Tenascin-C: Exploitation and collateral damage in cancer management.

Printed peptide arrays identify prognostic TNC serumantibodies in glioblastoma patients. Oncotarget (2015) 0.83

Tenascin-C serum levels and its prognostic power in non-small cell lung cancer. Oncotarget (2016) 0.78

A hypermorphic epithelial β-catenin mutation facilitates intestinal tumorigenesis in mice in response to compounding WNT-pathway mutations. Dis Model Mech (2015) 0.75

Tumor microenvironment tenascin-C promotes glioblastoma invasion and negatively regulates tumor proliferation. Neuro Oncol (2015) 0.75

Glioma Stem Cells but Not Bulk Glioma Cells Upregulate IL-6 Secretion in Microglia/Brain Macrophages via Toll-like Receptor 4 Signaling. J Neuropathol Exp Neurol (2016) 0.75

Quantitative proteomics identify Tenascin-C as a promoter of lung cancer progression and contributor to a signature prognostic of patient survival. Proc Natl Acad Sci U S A (2017) 0.75

Shear force-based genetic screen reveals negative regulators of cell adhesion and protrusive activity. Proc Natl Acad Sci U S A (2017) 0.75

Antiangiogenic therapy elicits malignant progression of tumors to increased local invasion and distant metastasis. Cancer Cell (2009) 16.06

Vascular endothelial growth factor: basic science and clinical progress. Endocr Rev (2004) 11.69

Rapid vascular regrowth in tumors after reversal of VEGF inhibition. J Clin Invest (2006) 6.12

Function and biological roles of the Dickkopf family of Wnt modulators. Oncogene (2006) 5.12

Molecular imaging in cancer. Science (2006) 5.01

RNA pseudoknots that inhibit human immunodeficiency virus type 1 reverse transcriptase. Proc Natl Acad Sci U S A (1992) 3.46

A tenascin-C aptamer identified by tumor cell SELEX: systematic evolution of ligands by exponential enrichment. Proc Natl Acad Sci U S A (2003) 3.28

RNA-based therapeutics: current progress and future prospects. Chem Biol (2012) 3.01

VEGF targets the tumour cell. Nat Rev Cancer (2013) 2.71

Tumor targeting by an aptamer. J Nucl Med (2006) 2.68

Radiation and the microenvironment - tumorigenesis and therapy. Nat Rev Cancer (2005) 2.65

Tissue repair and the dynamics of the extracellular matrix. Int J Biochem Cell Biol (2004) 2.59

Tenascin-C induced signaling in cancer. Cancer Lett (2006) 2.21

ATM-dependent DNA damage-independent mitotic phosphorylation of H2AX in normally growing mammalian cells. Mol Biol Cell (2005) 2.13

Transforming growth factor beta (TGF-beta) and inflammation in cancer. Cytokine Growth Factor Rev (2009) 1.95

The role of extracellular matrix in postinflammatory wound healing and fibrosis. FASEB J (1994) 1.93

The linear-quadratic model is inappropriate to model high dose per fraction effects in radiosurgery. Semin Radiat Oncol (2008) 1.93

Exploiting the glioblastoma peptidome to discover novel tumour-associated antigens for immunotherapy. Brain (2012) 1.92

The radiation-induced fibroatrophic process: therapeutic perspective via the antioxidant pathway. Radiother Oncol (2004) 1.92

Tenascin-C aptamers are generated using tumor cells and purified protein. J Biol Chem (2001) 1.81

The matrix metalloproteinase stromelysin-1 acts as a natural mammary tumor promoter. Oncogene (2000) 1.77

The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal (2009) 1.72

Expression of autoactivated stromelysin-1 in mammary glands of transgenic mice leads to a reactive stroma during early development. Am J Pathol (1998) 1.64

Second malignant neoplasms and cardiovascular disease following radiotherapy. J Natl Cancer Inst (2012) 1.64

Interference of tenascin-C with syndecan-4 binding to fibronectin blocks cell adhesion and stimulates tumor cell proliferation. Cancer Res (2001) 1.62

Association of an extracellular matrix gene cluster with breast cancer prognosis and endocrine therapy response. Clin Cancer Res (2008) 1.61

VEGF-A and Tenascin-C produced by S100A4+ stromal cells are important for metastatic colonization. Proc Natl Acad Sci U S A (2011) 1.60

Human Dkk-1, a gene encoding a Wnt antagonist, responds to DNA damage and its overexpression sensitizes brain tumor cells to apoptosis following alkylation damage of DNA. Oncogene (2002) 1.59

Clinical experience with alpha-particle emitting 211At: treatment of recurrent brain tumor patients with 211At-labeled chimeric antitenascin monoclonal antibody 81C6. J Nucl Med (2007) 1.57

Application of locked nucleic acids to improve aptamer in vivo stability and targeting function. Nucleic Acids Res (2004) 1.54

68Ga-labeled inhibitors of prostate-specific membrane antigen (PSMA) for imaging prostate cancer. J Med Chem (2010) 1.51

Advances in tenascin-C biology. Cell Mol Life Sci (2011) 1.50

Radioimmunotherapy with Tenarad, a 131I-labelled antibody fragment targeting the extra-domain A1 of tenascin-C, in patients with refractory Hodgkin's lymphoma. Eur J Nucl Med Mol Imaging (2014) 1.45

Radiation-induced hypoxia may perpetuate late normal tissue injury. Int J Radiat Oncol Biol Phys (2001) 1.42

Tenascin during gut development: appearance in the mesenchyme, shift in molecular forms, and dependence on epithelial-mesenchymal interactions. J Cell Biol (1988) 1.40

Imaging biomarkers predict response to anti-HER2 (ErbB2) therapy in preclinical models of breast cancer. Clin Cancer Res (2009) 1.35

Tenascins and the importance of adhesion modulation. Cold Spring Harb Perspect Biol (2011) 1.29

Microarray analysis of radiation response genes in primary human fibroblasts. Int J Radiat Oncol Biol Phys (2006) 1.28

Regulation of death receptor signaling and apoptosis by ceramide. Pharmacol Res (2003) 1.27

Tenascin-C upregulation by transforming growth factor-beta in human dermal fibroblasts involves Smad3, Sp1, and Ets1. Oncogene (2004) 1.24

Tumor-targeting properties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res (2006) 1.23

Fitting the linear-quadratic model to detailed data sets for different dose ranges. Phys Med Biol (2006) 1.16

CYR61 and alphaVbeta5 integrin cooperate to promote invasion and metastasis of tumors growing in preirradiated stroma. Cancer Res (2008) 1.15

Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int J Dev Biol (2011) 1.13

Salvage radioimmunotherapy with murine iodine-131-labeled antitenascin monoclonal antibody 81C6 for patients with recurrent primary and metastatic malignant brain tumors: phase II study results. J Clin Oncol (2006) 1.12

Radiotherapy for renal-cell carcinoma. Lancet Oncol (2014) 1.08

Molecular pathways: emerging pathways mediating growth, invasion, and metastasis of tumors progressing in an irradiated microenvironment. Clin Cancer Res (2012) 1.07

Expression and immune function of tenascin-C. Crit Rev Immunol (2011) 1.04

Radiotherapy suppresses angiogenesis in mice through TGF-betaRI/ALK5-dependent inhibition of endothelial cell sprouting. PLoS One (2010) 1.03

Intralesional radioimmunotherapy of malignant gliomas. An effective treatment in recurrent tumors. Cancer (1994) 1.02

Rational use of intensity-modulated radiation therapy: the importance of clinical outcome. Semin Radiat Oncol (2012) 1.02

Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the potency of chemotherapy. Clin Cancer Res (2008) 1.01

Pre-targeted locoregional radioimmunotherapy with 90Y-biotin in glioma patients: phase I study and preliminary therapeutic results. Cancer Biother Radiopharm (2001) 1.00

Switch to an invasive growth phase in melanoma is associated with tenascin-C, fibronectin, and procollagen-I forming specific channel structures for invasion. J Pathol (2006) 1.00

Growth promoting signaling by tenascin-C [corrected]. Cancer Res (2004) 0.99

A pilot study: 131I-antitenascin monoclonal antibody 81c6 to deliver a 44-Gy resection cavity boost. Neuro Oncol (2008) 0.99

Cell adhesion to the extracellular matrix protein fibronectin modulates radiation-dependent G2 phase arrest involving integrin-linked kinase (ILK) and glycogen synthase kinase-3beta (GSK-3beta) in vitro. Br J Cancer (2003) 0.99

Tenascin-C is an innate broad-spectrum, HIV-1-neutralizing protein in breast milk. Proc Natl Acad Sci U S A (2013) 0.96

Value of fibrosis markers for staging liver fibrosis in patients with precirrhotic alcoholic liver disease. Alcohol Clin Exp Res (2008) 0.96

Role of Radiation-induced TGF-beta Signaling in Cancer Therapy. Mol Cell Pharmacol (2009) 0.95

Binding of αvβ1 and αvβ6 integrins to tenascin-C induces epithelial-mesenchymal transition-like change of breast cancer cells. Oncogenesis (2013) 0.95

Acute tumor vascular effects following fractionated radiotherapy in human lung cancer: In vivo whole tumor assessment using volumetric perfusion computed tomography. Int J Radiat Oncol Biol Phys (2007) 0.95

Acquired cisplatin resistance in the head-neck cancer cell line Cal27 is associated with decreased DKK1 expression and can partially be reversed by overexpression of DKK1. Int J Cancer (2008) 0.95

Vaccination against the extra domain-B of fibronectin as a novel tumor therapy. FASEB J (2010) 0.92

Three clinical-stage tumor targeting antibodies reveal differential expression of oncofetal fibronectin and tenascin-C isoforms in human lymphoma. Leuk Res (2009) 0.92

High prevalence of chronic myocarditis in dilated cardiomyopathy referred for left ventriculoplasty: expression of tenascin C as a possible marker for inflammation. Hum Pathol (2009) 0.92

Therapeutic vaccination against fibronectin ED-A attenuates progression of metastatic breast cancer. Oncotarget (2014) 0.92

Priming and potentiation of DNA damage response by fibronectin in human colon cancer cells and tumor-derived myofibroblasts. Int J Oncol (2011) 0.89

Clinical significance of serum tenascin-C levels in breast cancer. Tumour Biol (2014) 0.89

Combination of temozolomide with immunocytokine F16-IL2 for the treatment of glioblastoma. Br J Cancer (2010) 0.89

A multimodal nanoparticle-based cancer imaging probe simultaneously targeting nucleolin, integrin αvβ3 and tenascin-C proteins. Biomaterials (2010) 0.89

Serum tenascin-C is an indicator of inflammatory bowel disease activity. Int J Colorectal Dis (2001) 0.89

How does ionizing irradiation contribute to the induction of anti-tumor immunity? Front Oncol (2012) 0.88

Tenascin-C in serum: a questionable tumor marker. Int J Cancer (1995) 0.88

Advances in radiotherapy. BMJ (2012) 0.88

Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep (2013) 0.87

Clinical significance of serum tenascin-c levels in epithelial ovarian cancer. Tumour Biol (2014) 0.87

Suppression of human brain tumor with interference RNA specific for tenascin-C. Cancer Biol Ther (2006) 0.87

Promising human brain tumors therapy with interference RNA intervention (iRNAi). Cancer Biol Ther (2010) 0.87

Expression of 72-kDa gelatinase (MMP-2), collagenase (MMP-1), and tissue metalloproteinase inhibitor (TIMP) in primary pig skin fibroblast cultures derived from radiation-induced skin fibrosis. J Invest Dermatol (1994) 0.86

A systems biology view of blood vessel growth and remodelling. J Cell Mol Med (2013) 0.86

Comparative immunohistochemistry of L19 and F16 in non-small cell lung cancer and mesothelioma: two human antibodies investigated in clinical trials in patients with cancer. Lung Cancer (2008) 0.86

A comparative analysis of oncofetal fibronectin and tenascin-C incorporation in tumour vessels using human recombinant SIP format antibodies. Histochem Cell Biol (2010) 0.85

Locally applied cilostazol suppresses neointimal hyperplasia and medial thickening in a vein graft model. Ann Thorac Cardiovasc Surg (2007) 0.85

Pharmacological prevention of radiation-induced dry eye-an experimental study in a rabbit model. Graefes Arch Clin Exp Ophthalmol (2007) 0.85

Comparative effectiveness research in radiation oncology: stereotactic radiosurgery, hypofractionation, and brachytherapy. Semin Radiat Oncol (2014) 0.85

Tenascin C promiscuously binds growth factors via its fifth fibronectin type III-like domain. PLoS One (2013) 0.84

Pre-irradiation of mouse mammary gland stimulates cancer cell migration and development of lung metastases. Br J Cancer (2013) 0.84

AngioMatrix, a signature of the tumor angiogenic switch-specific matrisome, correlates with poor prognosis for glioma and colorectal cancer patients. Oncotarget (2014) 0.84

Antibody-based delivery of interleukin-2 to neovasculature has potent activity against acute myeloid leukemia. Sci Transl Med (2013) 0.83

A murine model for the study of molecular pathogenesis of radiation proctitis. Int J Radiat Oncol Biol Phys (2010) 0.83

A multivariate analysis of patients with brain tumors treated with ATN-RNA. Acta Pol Pharm (2009) 0.82

Epithelial tenascin predicts obliterative airway disease. J Heart Lung Transplant (2008) 0.82

Locally applied cilostazol suppresses neointimal hyperplasia by inhibiting tenascin-C synthesis and smooth muscle cell proliferation in free artery grafts. J Thorac Cardiovasc Surg (2004) 0.81

Quantitative analysis of three-dimensional human mammary epithelial tissue architecture reveals a role for tenascin-C in regulating c-met function. Am J Pathol (2009) 0.80

A comparative immunofluorescence analysis of three clinical-stage antibodies in head and neck cancer. Head Neck Oncol (2011) 0.80

Phase 0 microdosing PET study using the human mini antibody F16SIP in head and neck cancer patients. J Nucl Med (2013) 0.80

Different patterns of fibronectin and tenascin-C splice variants expression in primary and metastatic melanoma lesions. Exp Dermatol (2011) 0.79

Unlike tenascin-X, tenascin-C is highly up-regulated in pig cutaneous and underlying muscle tissue developing fibrosis after necrosis induced by very high-dose gamma radiation. Radiat Res (1998) 0.79

Tenascin-C: a key molecule in graft stenosis. Cardiovasc Res (2007) 0.79

Tenascin-C is an endogenous activator of Toll-like receptor 4 that is essential for maintaining inflammation in arthritic joint disease. Nat Med (2009) 3.87

CD24 expression causes the acquisition of multiple cellular properties associated with tumor growth and metastasis. Cancer Res (2005) 2.53

The role of tenascin-C in tissue injury and tumorigenesis. J Cell Commun Signal (2009) 1.72

Advances in tenascin-C biology. Cell Mol Life Sci (2011) 1.50

Mutations in Lama1 disrupt retinal vascular development and inner limiting membrane formation. J Biol Chem (2010) 1.19

Fibronectin and tenascin-C: accomplices in vascular morphogenesis during development and tumor growth. Int J Dev Biol (2011) 1.13

RGD-independent cell adhesion via a tissue transglutaminase-fibronectin matrix promotes fibronectin fibril deposition and requires syndecan-4/2 α5β1 integrin co-signaling. J Biol Chem (2010) 1.05

Role of laminins in physiological and pathological angiogenesis. Int J Dev Biol (2011) 1.01

Combined proton and photon conformal radiotherapy for intracranial atypical and malignant meningioma. Int J Radiat Oncol Biol Phys (2009) 1.00

Growth promoting signaling by tenascin-C [corrected]. Cancer Res (2004) 0.99

Proton beam radiotherapy for uveal melanoma: results of Curie Institut-Orsay proton therapy center (ICPO). Int J Radiat Oncol Biol Phys (2006) 0.97

SNP array analysis reveals novel genomic abnormalities including copy neutral loss of heterozygosity in anaplastic oligodendrogliomas. PLoS One (2012) 0.94

Tenascin-W is a novel marker for activated tumor stroma in low-grade human breast cancer and influences cell behavior. Cancer Res (2007) 0.94

Endothelin receptor type B counteracts tenascin-C-induced endothelin receptor type A-dependent focal adhesion and actin stress fiber disorganization. Cancer Res (2007) 0.93

Myofibroblast distribution in Dupuytren's cords: correlation with digital contracture. J Hand Surg Am (2009) 0.92

Functional role of laminin α1 chain during cerebellum development. Cell Adh Migr (2012) 0.90

Post-transcriptional regulation of alpha-smooth muscle actin determines the contractile phenotype of Dupuytren's nodular cells. J Cell Physiol (2010) 0.88

Combined lysophosphatidic acid/platelet-derived growth factor signaling triggers glioma cell migration in a tenascin-C microenvironment. Cancer Res (2008) 0.88

Tenascin-C downregulates wnt inhibitor dickkopf-1, promoting tumorigenesis in a neuroendocrine tumor model. Cell Rep (2013) 0.87

A treatment planning comparison of combined photon-proton beams versus proton beams-only for the treatment of skull base tumors. Int J Radiat Oncol Biol Phys (2007) 0.87

Laminin α5 guides tissue patterning and organogenesis. Cell Adh Migr (2012) 0.86

Novel function of tenascin-C, a matrix protein relevant to atherosclerosis, in platelet recruitment and activation under flow. Arterioscler Thromb Vasc Biol (2010) 0.85

MicroRNA epigenetics: a new avenue for wound healing research. BioDrugs (2011) 0.84

Comparison of the dosimetries of 3-dimensions Radiotherapy (3D-RT) with linear accelerator and intensity modulated radiotherapy (IMRT) with helical tomotherapy in children irradiated for neuroblastoma. BMC Med Phys (2012) 0.83

The mTOR inhibitor RAD001 potentiates autophagic cell death induced by temozolomide in a glioblastoma cell line. Anticancer Res (2013) 0.82

Proton therapy in pediatric skull base and cervical canal low-grade bone malignancies. Int J Radiat Oncol Biol Phys (2008) 0.82

Chondroblastoma of the apex portion of petrousal bone. Childs Nerv Syst (2006) 0.81

The adhesion modulating properties of tenascin-W. Int J Biol Sci (2011) 0.81

An Innovative Fluorescent Semi-quantitative Methylation-specific PCR Method for the Determination of MGMT Promoter Methylation is Reflecting Intra-tumor Heterogeneity. Curr Cancer Drug Targets (2015) 0.79

Bilateral macular ischemia and severe visual loss following trastuzumab therapy. Acta Oncol (2011) 0.79

Impact of 3D conformal radiotherapy on lung function of patients with lung cancer: a prospective study. Respiration (2012) 0.78

Can exhaled NO fraction predict radiotherapy-induced lung toxicity in lung cancer patients? Radiat Oncol (2012) 0.78

Contribution of three-dimensional conformal intensity-modulated radiation therapy for women affected by bulky stage II supradiaphragmatic Hodgkin disease. Radiat Oncol (2013) 0.77

Abnormal Wnt and PI3Kinase signaling in the malformed intestine of lama5 deficient mice. PLoS One (2012) 0.77

Phosphonated chelates for nuclear imaging. Org Biomol Chem (2014) 0.76

Synthesis of an activated phosphonated bifunctional chelate with potential for PET imaging and radiotherapy. Org Biomol Chem (2012) 0.76

Special issue of Cell Adhesion & Migration on Tenascins: Defining their role in tissue homeostasis and cancer. Cell Adh Migr (2015) 0.76

Spatial organization of the tenascin-C microenvironment in experimental and human cancer. Cell Adh Migr (2015) 0.75

Early evaluation predicts pain relief of irradiated bone metastases: a single-center prospective study. BMC Palliat Care (2013) 0.75

Startups on the menu. Nat Biotechnol (2013) 0.75

Clinical complementarities between proton and carbon therapies. Radiother Oncol (2004) 0.75

Stem cells and matrix. Int J Biochem Cell Biol (2016) 0.75

Comparison of time taken from initial presentation to histological diagnosis of Glioblastoma Multiforme (GBM) in Birmingham, United Kingdom and Strasbourg, France. Clin Neurol Neurosurg (2011) 0.75

[PARP inhibitors: significant progress in cancer therapy]. Bull Cancer (2011) 0.75